Shares of Apple Inc were up 3.8% in early trading after Reuters exclusively reported that the company was moving forward with self-driving car technology and was targeting 2024 to produce a passenger vehicle

Lilly had previously said it would make one million doses of its single antibody treatment available by the end of the year

The reason why Exxon's stock has plunged is for more than the simple fact that oil has fallen out of favour by investors

Sectorally, barring pharma, all other sectors closed in green territory, with IT index ending 2.6% and banking indices closing 1.5% higher

A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?

Analysts expect a better show in Q1 thanks to a combination of factors such as overall business improvement in the Unites States and a pick-up in demand in the domestic market.

Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide

Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.

The competition to tap large molecule structured complex bio-similars or off-patent biotech drugs is heating up.

India has taken a lead here and going by the official figures, there are around 24 cancer biosimilar drugs in all that have already been approved by the Indian regulator since 2011.

Indian drug makers are slugging it out with Big Pharma over launch of biosimilars. Will they be able to hold their fort in this emerging space?

Stocks and oil have been strongly correlated in recent months as crude prices tanked to decade lows, and their movements in opposite directions during the session was notable to investors.

There is pressure by some sections within the US to downgrade India from 'watch list' to 'Priority foreign country'.

The profit for the second quarter period crossed Rs 700 crore. According to analysts, these were a good set of numbers given the challenges and the fact that it did not take any price hikes.

The exclusive rights for this product are applicable for the US, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.

Drug Controller General Dr GN Singh directed officials to compile list of veterinary drugs with details like date of approval, name of manufacturer, composition of product and its storage conditions.

It is still not clear who is severely impacted by the ban. Because if the impact was huge on any company, it would have by now informed the stock exchanges.